Contingent Value Rights: A Drafting Guide for Biopharma M&A

Contingent value rights have become a defining feature of biopharma M&A, appearing in under 10% of mid-cap public-target deals before 2019 but a quarter to a third of them in every year since 2023. They let a buyer pay less cash at signing while preserving upside for selling stockholders on a binary clinical, regulatory, or commercial catalyst, shifting the drafting battleground from price to the fine print of the milestone, the efforts covenant, and the enforcement machinery. This guide is organized around that fine print: what the market actually does, a term-by-term drafting analysis with side-by-side pro-buyer and pro-seller model clauses, the recent litigation now driving negotiation, and the 2025–2026 regulatory overlay that can make sales-based milestones materially harder to hit and to measure.